The Blue Knight

ChromaTan, Inc. Selected as a BLUE KNIGHT™ Company

Retrieved on: 
Tuesday, November 21, 2023
Research, Clinical Trials, Health Technology, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Safety, Plasma, Acceleration, Chemical engineering, ASPR, NIIMBL, FDA, Ecosystem, BLUE, Messenger, Pennsylvania State University, Chemical substance, Plasmid, NIH, HHS, Development, Bayard, Administration, The Blue Knight, Public, 3D printing, Fine chemical, Monoclonal antibody

ChromaTan, Inc., a bioprocess development company revolutionizing the 123-year-old traditional batch biopurification process through transformational next-generation biomanufacturing solutions, announced today that it has been selected as a BLUE KNIGHT™ company.

Key Points: 
  • ChromaTan, Inc., a bioprocess development company revolutionizing the 123-year-old traditional batch biopurification process through transformational next-generation biomanufacturing solutions, announced today that it has been selected as a BLUE KNIGHT™ company.
  • As a Blue Knight company, ChromaTan will gain access to the global JLABS ecosystem, a premier life science incubator program.
  • "We are excited to join JLABS as a Blue Knight company.
  • "I’m thrilled to see ChromaTan selected as a Blue Knight company.

Esperovax Awarded $1M for Development of an Oral COVID-19 RNA Vaccine under the HHS Project NextGen Initiative

Retrieved on: 
Tuesday, October 3, 2023
BLUE, Nextgen, Biomedical Advanced Research and Development Authority, University, Public, Johnson & Johnson, COVID-19, Anglo-Scandinavian, Infection, RNA, The Blue Knight, Development, Investigational New Drug, Animal, UTHealth School of Dentistry, BARDA, Disease, Vaccine

PLYMOUTH, Mich., Oct. 3, 2023 /PRNewswire/ -- Esperovax, a U.S.-based preclinical biopharmaceutical company and a BLUE KNIGHT™ resident company, is receiving an award for $ 1 M to further develop a yeast-based oral COVID-19 RNA vaccine candidate as part of the BLUE KNIGHT™ QuickFire Challenge : Accelerating Project NextGen.

Key Points: 
  • PLYMOUTH, Mich., Oct. 3, 2023 /PRNewswire/ -- Esperovax, a U.S.-based preclinical biopharmaceutical company and a BLUE KNIGHT™ resident company, is receiving an award for $ 1 M to further develop a yeast-based oral COVID-19 RNA vaccine candidate as part of the BLUE KNIGHT™ QuickFire Challenge : Accelerating Project NextGen.
  • This award will support critical studies aimed at demonstrating vaccine safety and immunoprotection in orally vaccinated animals challenged with different COVID-19 virus variants.
  • Esperovax is collaborating with Dr. Slobodan Paessler at the University of Texas Medical Branch – Galveston to conduct these studies.
  • Blue Knight, a joint initiative between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA), collaborates with companies to accelerate innovation against emerging health security threats.

HDT Bio Selected to Join BLUE KNIGHT™

Retrieved on: 
Monday, November 7, 2022
Biotechnology, Pharmaceutical, Medical Supplies, Oncology, General Health, Health, Infectious Diseases, Clinical Trials, The Blue Knight, RNA, Public health, National Cancer Institute, Therapy, RNA transfection, SaRNA, HDT, Administration, Human services, Johnson & Johnson, Biomedical Advanced Research and Development Authority, Unitary state, Military personnel, Vaccine, COVID-19, Office of Inspector General, U.S. Department of Health and Human Services, Incubator, Infection, View, U.S. Department of Defense Strategy for Operating in Cyberspace, Government, HHS, Immune system, Development, Technology, ASPR, Cancer, BARDA

We are grateful to JLABS and BARDA to be named a Blue Knight company , said HDT Bio CEO Steve Reed.

Key Points: 
  • We are grateful to JLABS and BARDA to be named a Blue Knight company , said HDT Bio CEO Steve Reed.
  • HDT Bio is focused on applying self-amplifying RNA (saRNA) with its proprietary LION delivery system to develop immunotherapies for infectious diseases and cancer.
  • HDT Bio also is collaborating with National Cancer Institute to develop saRNA vaccines to prevent and treat multiple cancers.
  • Through Blue Knight, HDT Bio will be a virtual company in JLABS , a global network of life science incubators.

ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray

Retrieved on: 
Wednesday, May 11, 2022
The Blue Knight, Hospital, BARDA, Nasal mucosa, BLUE, Company, GLOBE, Development, Human services, Biomedical Advanced Research and Development Authority, U.S. Department of Defense Strategy for Operating in Cyberspace, Infection, Fever, Office of Inspector General, U.S. Department of Health and Human Services, Virus, Human, Johnson & Johnson, Severe acute respiratory syndrome coronavirus 2, Family, Rhinovirus, Conference, CEO, Nose, Research, Interview, ENA, Epithelium, Johnson & Johnson COVID-19 vaccine, Risk, Pharmaceutical industry, Vaccine, H1N1

ENA Respiratory is the first Australian company to be selected to join Blue Knight.

Key Points: 
  • ENA Respiratory is the first Australian company to be selected to join Blue Knight.
  • Blue Knight offers a scientific and technological ecosystem for innovative, early-stage companies to develop strategically aligned technologies that aim to combat health threats and emerging infectious diseases.
  • As a Blue Knight company, ENA Respiratory will benefit from mentorship from experts from BARDA, the Johnson & Johnson Family of Companies, and a global network of innovators who could provide critical insight and support throughout INNA-051 development.
  • ENA Respiratorys self-administered nasal spray INNA-051 product is designed with the aim to stimulate the innate immunity in the nose, which is the preferential site of initial infection and replication of most respiratory viruses.

GRIP Molecular Announces BLUE KNIGHT™ Acceptance

Retrieved on: 
Wednesday, March 2, 2022
Company, Johnson & Johnson Vision, Family, Diagnosis, Biomedical Advanced Research and Development Authority, CIC, GRIP, BARDA, Johnson & Johnson, Cambridge Innovation Center, RSV, Biology, COVID-19, Development, The Blue Knight, Johnson, Kendall Square, CEO, Respiratory tract, Electronics, Technology, Saliva, Infection, Pharmaceutical industry, Medical device

ST. PAUL, Minn., March 1, 2022 /PRNewswire/ -- GRIP Molecular Technologies, Inc. ('GRIP') ( www.GRIPMolecular.com ), an early-stage diagnostic company, announced that it has been accepted into Blue Knight , a joint initiative between Johnson and Johnson Innovation JLABS ('JLABS') and the Biomedical Advanced Research and Development Authority (BARDA).

Key Points: 
  • ST. PAUL, Minn., March 1, 2022 /PRNewswire/ -- GRIP Molecular Technologies, Inc. ('GRIP') ( www.GRIPMolecular.com ), an early-stage diagnostic company, announced that it has been accepted into Blue Knight , a joint initiative between Johnson and Johnson Innovation JLABS ('JLABS') and the Biomedical Advanced Research and Development Authority (BARDA).
  • Through Blue Knight, GRIP will receive fee assistance towards its JLABS residency at JPOD @ Boston, located at the Cambridge Innovation Center's (CIC) location in Kendall Square, Cambridge Massachusetts.
  • We view admittance into Blue Knight as further recognition of the potentially transformative impact the GRIP diagnostic technology could have on healthcare."
  • For more information about GRIP Molecular and associated investment opportunities please contact:

Protinhi Therapeutics selected as part of BLUE KNIGHT™ collaboration for pandemic preparedness

Retrieved on: 
Tuesday, November 16, 2021
Diamond, The Blue Knight, TC, Family, Protease, BLUE, Flaviviridae, Therapy, Ecosystem, Fever Dream, Dengue fever, Compound, Infection, CEO, Coronavirus, Johnson & Johnson, COVID-19, BARDA, Biomedical Advanced Research and Development Authority, Protein, West Nile virus, Research, Development, Virus, Patient, Chikungunya, Vaccine, Pharmaceutical industry

NIJMEGEN, The Netherlands, Nov. 16, 2021 /PRNewswire/ -- Protinhi Therapeutics, a Netherlands-based biotechnology company specializing in protease inhibition with the aim to combat viral infectious diseases, today announced it has been selected to join BLUE KNIGHT™, a global community of early-stage biotech companies.

Key Points: 
  • Blue Knightis a joint initiative created between Johnson & Johnson Innovation JLABS ('JLABS') and the Biomedical Advanced Research and Development Authority (BARDA).
  • Protinhi is the third European biotech startup to become a Blue Knight company, and its selection highlights the growth trajectory of a company operating in a priority area with high unmet medical need.
  • Operationally active since 2016, Protinhi specializes in the development of novel antivirals against upcoming viral health threats.
  • [ii]
    As a Blue Knight company, Protinhi can benefit from continuing support and assistance within the JLABS' global innovation ecosystem.

Protinhi Therapeutics selected as part of BLUE KNIGHT™ collaboration for pandemic preparedness

Retrieved on: 
Tuesday, November 16, 2021
Diamond, The Blue Knight, TC, Family, Protease, BLUE, Flaviviridae, Therapy, Ecosystem, Fever Dream, Dengue fever, Compound, Infection, CEO, Coronavirus, Johnson & Johnson, COVID-19, BARDA, Biomedical Advanced Research and Development Authority, Protein, West Nile virus, Research, Development, Virus, Patient, Chikungunya, Vaccine

NIJMEGEN, The Netherlands, Nov. 16, 2021 /PRNewswire/ -- Protinhi Therapeutics, a Netherlands-based biotechnology company specializing in protease inhibition with the aim to combat viral infectious diseases, today announced it has been selected to join BLUE KNIGHT™, a global community of early-stage biotech companies.

Key Points: 
  • Blue Knightis a joint initiative created between Johnson & Johnson Innovation JLABS ('JLABS') and the Biomedical Advanced Research and Development Authority (BARDA).
  • Protinhi is the third European biotech startup to become a Blue Knight company, and its selection highlights the growth trajectory of a company operating in a priority area with high unmet medical need.
  • Operationally active since 2016, Protinhi specializes in the development of novel antivirals against upcoming viral health threats.
  • [ii]
    As a Blue Knight company, Protinhi can benefit from continuing support and assistance within the JLABS' global innovation ecosystem.

CHO Plus Announces Acceptance Into BLUE KNIGHT™

Retrieved on: 
Tuesday, August 24, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Genetics, Johnson & Johnson, BARDA, Investor, Disease, Biomedical Advanced Research and Development Authority, Virus, Cancer, The Blue Knight, Pandemic, Health, Golgi apparatus, CA, Antibody, Cell, Development, Endoplasmic reticulum, Vaccine, CEO, Technology, Fine chemical

Blue Knight is a joint initiative created between Johnson & Johnson Innovation and the Biomedical Advanced Research and Development Authority (BARDA).

Key Points: 
  • Blue Knight is a joint initiative created between Johnson & Johnson Innovation and the Biomedical Advanced Research and Development Authority (BARDA).
  • CHO Plus technology could expand the existing manufacturing capacity for production of therapeutic proteins and vaccines thus making the company a good fit for the mission of the Blue Knight program.
  • Through dedicated mentorship, CHO Plus will work with BARDA representatives and associates toward mutually beneficial goals.
  • James Panek, CHO Plus COO, added: We are grateful for the confidence the Blue Knight initiative has shown in our technology, and for the financial support.